Blood cancers, anaemias, haemophilia and other blood disorders share some commonalities when it comes to market access. Among others, these diseases:
· require a mix of inpatient and outpatient patient management that has an impact on market access requirements and pathways;
· patients are often subject to bone marrow and stem cell transplants with the connected high risks and costs;
· some of these diseases are genetic or can affect relatively young patients;
· new technologies like cell and gene therapies promise a cure for some of these patients.
At forethought access, we support our customers with front line knowledge of market access pathways, decision makers and drivers combined with a general understanding of scientific and clinical peculiarities of these diseases and their treatments.